-
A New Hope for Peanut Allergy Sufferers: FDA Grants Fast Track Designation to PVX108
Revolutionizing Peanut Allergy Treatment For millions of people living with a peanut allergy, even accidental exposure can cause life-threatening reactions. Recently, the biotechnology company Aravax reached a major milestone in the fight to change this reality. The U.S. Food and Drug Administration (FDA) has officially granted Fast Track designation to the company’s lead investigational product,…
-
A New Hope: FDA Grants Priority Review for Jemperli in Locally Advanced Rectal Cancer
NYSE: $GSK Advancing Treatment for dMMR/MSI-H Rectal Cancer There is promising news in the landscape of oncology as the U.S. Food and Drug Administration (FDA) has officially accepted a supplemental Biologics License Application (sBLA) for Jemperli (dostarlimab-gxly). This application has been granted Priority Review, signaling a potential shift in how we approach locally advanced rectal…
-
A New Frontier: FDA Approves Imfinzi for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
A Significant Breakthrough in Bladder Cancer Care For patients facing non-muscle invasive bladder cancer (NMIBC), treatment options have historically been limited, particularly for those whose cancer does not respond to standard BCG therapy. Recently, the landscape of care shifted with the FDA approval of Imfinzi (durvalumab), marking a major milestone as the first and only…
-
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors
NASDAQ: $IDYA IDEAYA Biosciences’ recent exclusive license agreement with Hengrui Pharma for SHR-4849 marks a significant milestone in the field of oncology therapeutics. This partnership brings forth a promising novel Phase 1 DLL3 Topo-I-Payload Antibody-Drug Conjugate (ADC) targeting Small Cell Lung Cancer (SCLC) and Neuroendocrine Tumors (NET). The collaboration between these two renowned pharmaceutical companies…
-
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
NASDAQ: $CGEM 1. Introduction to CLN-617: A Novel Fusion Protein The field of oncology research continues to evolve with the aim of developing innovative and effective therapies to combat cancer. In this regard, Cullinan Oncology has recently announced the initiation of a Phase 1 clinical trial to evaluate the potential of CLN-617, a novel fusion…